Effects of absorption enhancers in chloroquine suppository formulations: I. In vitro release characteristics.
The need to develop chloroquine suppository formulations that yield optimal bioavailability of the drug has been emphasized. This study demonstrates the effects of incorporation of known absorption-enhancing agents (nonionic surfactants and sodium salicylate) on the in vitro release characteristics of chloroquine from polyethylene glycol (1000:4000, 75:25%, w/w) suppositories. The release rates were determined using a modification of the continuous flow bead-bed dissolution apparatus for suppositories. Results showed that the extent of drug release from suppositories containing any of three surfactants (Tween 20, Tween 80 and Brij 35) was 100%, whereas 88% release was obtained with control formulation (without enhancer) (P<0.05). However, Tween 20 was more effective than Brij 35 and Tween 80 in improving the drug release rate. There was a concentration-dependent effect with Tween 20, and 4% (w/w) of this surfactant was associated with the highest increase in the rate of drug release from the suppositories. Sodium salicylate at a concentration of 25% (w/w) also significantly enhanced the drug release rate, but a higher concentration of the adjuvant markedly reduced both the rate and extent of drug release. Combined incorporation of Tween 20 and sodium salicylate did not significantly modify (P0.05) the rate of drug release when compared to the effect of the more effective single agent. Due to their effects in improving the drug release profiles coupled with their intrinsic absorption-promoting properties, it is suggested that incorporation of 4% (w/w) Tween 20 and/or 25% (w/w) sodium salicylate in the composite polyethylene glycol chloroquine suppository formulations, may result in enhancement of rectal absorption of the drug. This necessitates an in vivo validation.
Onyeji
C O
CO
Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria. conyeji@oauife.edu.ng
Adebayo
A S
AS
Babalola
C P
CP
D000042:Absorption; D002738:Chloroquine / Q000493:pharmacokinetics*; D066298:In Vitro Techniques; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000737:chemistry*; D011136:Polysorbates / Q000737:chemistry; D012980:Sodium Salicylate / Q000737:chemistry*; D013488:Suppositories / Q000493:pharmacokinetics*; D013501:Surface-Active Agents / Q000737:chemistry*; D013997:Time Factors
D011136:Polysorbates; D013488:Suppositories; D013501:Surface-Active Agents; D000077423:Polidocanol; D011092:Polyethylene Glycols; D002738:Chloroquine; D012980:Sodium Salicylate